Enzolytics Inc (ENZC)

[Santes8]

The differentiator is in the way the treatment works. We know other manufacturers (Lilly) are having issues attaching to immutable sites (which BioClonetics claims to do). So the buyout or partnership opportunity is somewhat of a licensing deal with us. They need to use our patented tech to produce treatment as soon as possible, so they cannot wait out the patent. You see this all the time in Biotech. They either need to wait out the patent exp, license the rights, or buy us out at an est value multiple to prevent competitiveness